Browsing by Author "Gupta, Anshuman"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Drug abuse and ACS in the very young (less than 30 years): Demographic, clinical and angiographic profile
    (Elsevier, 2024-10) Chhabra, Shibba Takkar; Kaur, Gurleen; Kapoor, Samir; Kapila, Aastha; Kaur, Gagandeep; Jain, Prannav; kumar, Pankaj; Bansal, Namita; Bansal, Mamta; Gupta, Anshuman; Batta, Akash; Singal, Gautam; Goyal, Abhishek; Tandon, Rohit; Aslam, Naved; Mohan, Bishav; Wander, Gurpreet Singh
    Aim: To identify incidence, type of drug abuse study clinical and angiographic profile in very young population presenting with acute coronary syndrome (ACS). Materials and methods: All consecutive patients less than 30 years with ACS included and segregated into Group 1 and 2 (with and without drug abuse respectively) Result: n = 153; n = 17 in group 1 of whom 35.29 % consumed opium, 17.64 % energy drinks, 17.64 % whey protein supplements, 17.64 % inhaled marijuana, 5.88 % heroin and spasmoproxyvon and 23.52 % multi- substance abusers. STEMI, Single vessel disease and urban domicile were predominant. Rising trends of drug abuse were identified in prospective (28.20 %) versus retrospective (5.30 %) timeframe (p = 0.011). Conclusion: Rising trends of drug abuse, a potentially modifiable risk factor of ACS in the young are alarming. Strict regulations are needed to curb this menace.
  • No Thumbnail Available
    Item
    Torsemide as a Primary Choice in Edema Associated with Heart Failure
    (Journal of Indian Medical Association, 2024-09) Ezhilan, Janakiraman; Dighe, Sunil; Shah, Chetan; Tiwaskar, Mangesh; Chopra, Vikas; Patil, Rahul; Srivastava, Prabin; Mahilmaran, Asha; Pradhan, Akshyaya; Rahman, Suzaur; Malviya, Amit; Gupta, Anshuman; Teja, Phani; Francis, Febin; Sugumaran, Amarnath
    Heart failure (HF) is the fastest-growing disease with a higher fatality rate. The most differentiating feature of HF is pulmonary or peripheral edema, which is characterized by a gradient between intravascular and extravascular pressure. Loop diuretics were chosen as the primary treatment for edema associated with HF due to their efficacy and early onset of action. If an oral dose had not been provided, intravenous (IV) administration of torsemide, or equal doses of furosemide and bumetanide, was preferred. However, the key variables for selecting and administering loop diuretics are their pharmacological qualities as well as their clinical efficacy. Torsemide has greater bioavailability, a higher rate of absorption, a longer duration of action, and lesser ototoxicity, making it the primary choice in the management of edematous HF